Highlights

  • Argenica reported FY26 Revenue of $5.70 million, up 53% year-on-year.
  • The company completed its Phase 2 trial of xaranetide in acute ischaemic stroke patients.
  • Xaranetide concussion data was selected for oral presentation at the 2026 International NeuroTrauma Society meeting.
  • Cash and cash equivalents stood at $6.36 million at 30 June 2026.

Argenica Therapeutics Limited (ASX:AGN) continued advancing its neuroprotective therapeutic development program during FY26, with progress across clinical research, regulatory activities and preclinical studies.

The company reported revenue of $5.70 million for the year ended 30 June 2026, representing a 53% increase compared with the previous year. The result included Research and Development tax incentive income, government grant income and interest income.

The company recorded a net loss after tax of $1.37 million, an improvement from the $7.17 million loss reported in FY25. Research and development expenditure during the year was $4.21 million, including costs associated with completion of the Phase 2 xaranetide trial in acute ischaemic stroke patients, future Phase 2b trial planning, drug Manufacturing activities and regulatory consulting.

At 30 June 2026, Argenica held cash and cash equivalents of $6.36 million, compared with $10.56 million at the previous year end. The company reported a net asset position of $5.90 million.

Argenica’s primary focus remains the development of xaranetide, formerly known as ARG-007, a neuroprotective therapeutic designed to reduce brain tissue death following stroke and other acute neurological injuries.

Xaranetide Stroke Program Moves Towards Later-Stage Trial Planning

During FY26, Argenica completed its Phase 2 clinical trial of xaranetide in acute ischaemic stroke patients. The trial recruited patients across eight Australian hospitals with dedicated stroke care units.

The primary objective of the trial was to assess safety in patients undergoing endovascular thrombectomy, and this objective was successfully met.

The trial also evaluated secondary efficacy measures, including infarct Volume and functional outcomes. The company reported that more severe stroke patients showed a treatment effect, with post-hoc analysis identifying statistically significant improvements in FDA-validated functional outcomes in patients with larger infarct cores.

Following the Phase 2 results, Argenica began designing a targeted late-stage acute ischaemic stroke trial. The proposed trial is being developed as either a Phase 2b or seamless Phase 2b/3 study, with patient selection supported by stroke severity assessment and AI-enabled diagnostic tools.

The company is also progressing manufacturing activities with Corden Pharma in Europe to establish a scaled manufacturing process for future Clinical Trials and potential commercial supply.

Argenica has completed three assays requested by the US Food and Drug Administration following the clinical hold on its investigational new drug application for xaranetide.

Expanding Neuroprotection Research Beyond Stroke

Alongside its stroke program, Argenica continued exploring xaranetide across other neurological injury indications, including traumatic brain injury and concussion.

In September 2026, the company announced that its preclinical concussion study had been selected for oral presentation at the 2026 Meeting of the International NeuroTrauma Society.

The study investigated a single low dose of xaranetide administered intravenously 30 minutes after a second mild traumatic brain injury. The research identified reductions in markers associated with neuroinflammation, oxidative stress and axonal injury.

The effects were observed across multiple brain regions, including the cortex, corpus callosum, dentate gyrus and ventral tegmental area, with effects sustained to Day 11 following injury.

The company continues evaluating xaranetide’s potential across acute neurological injuries while progressing its lead clinical development pathway in stroke.

Argenica’s future activities include finalising the clinical trial protocol, progressing regulatory engagement, preparing manufacturing capability and evaluating opportunities for strategic partnerships.

Key Insights

Argenica Therapeutics’ FY26 period was focused on advancing xaranetide through clinical development, regulatory preparation and broader neurological research. The company progressed its stroke program following Phase 2 results while expanding preclinical investigation into traumatic brain injury and concussion.